Skip to main content

Table 1 Characteristics of included patients

From: Monitoring patients with juvenile idiopathic arthritis using health-related quality of life

 

Total

cJADAS-71 < =1.5 or < =2.5a

cJADAS-71 > 1.5 or > 2.5b

Patients, n (%)

68

35

33

Female, n (%)

47 (69)

24 (69)

23 (70)

JIA Subcategory, n (%)

Oligoarticular JIA persistent

27 (40)

12 (34)

15 (45)

Oligoarticular JIA extended

6 (9)

3 (9)

3 (9)

Polyarticular JIA RF-

15 (22)

9 (26)

6 (18)

Polyarticular JIA RF+

5 (7)

1 (3)

4 (12)

Psoriatic Arthritis

7 (10)

6 (17)

1 (3)

Enthesitis Related Arthritis

5 (7)

2 (6)

3 (9)

Systemic JIA

1 (2)

1 (3)

0 (−)

Undifferentiated JIA

2 (3)

1 (3)

1 (3)

Age at visit, median (IQR), y

13.6 (10.5–16.4)

13.3 (11.0–15.6)

14.1 (9.0–16.9)

Age at disease onset, median (IQR), y

7.6 (3.1–12.1)

6.7 (3.0–11.2)

9.4 (3.4–13.6)

Disease duration, median (IQR), y

4.6 (1.5–7.7)

6.4 (2.7–8.4)

2.4 (1.2–6.3)

cJADAS-71, median (IQR)

1.8 (0.1–6.1)

0.1 (0.0–0.7)

6.5 (4.0–9.5)

Treatment at Visit

Biologic DMARD, n (%)

  Adalimumab

17 (25)

10 (29)

7 (21)

  Etanercept

8 (12)

4 (11)

4 (12)

  Golimumab

4 (6)

0 (−)

4 (12)

Synthetic DMARD, n (%)

  Methotrexate

30 (44)

17 (49)

13 (39)

  Other DMARD

5 (7)

3 (9)

2 (6)

No Biologic or Synthetic DMARD n (%)

24 (35)

12 (34)

12 (36)

  1. cJADAS-71: clinical juvenile arthritis disease activity score with 71 joint count; DMARD: disease modifying anti-rheumatic drug; IQR: interquartile range. aLow disease activity for oligoarticular or polyarticular JIA, respectively. b Moderate or high disease activity for oligoarticular or polyarticular JIA, respectively